-
Computer Aided Detection Software for Intestinal Polyps in Lower Gastrointestinal Endoscopy Approved for Marketing
2023-05-12
Recently, the innovative product Computer Aided Detection Software for Intestinal Polyps in Lower Gastrointestinal Endoscopy of Wuhan ENDOANGEL Medical Technology Co., Ltd is approved by China NMPA.
-
Self-expanding Radioactive Seed-Carried Biliary Stent Approved for Marketing
2023-05-11
On May 11, 2023, the innovative product Self-expanding Radioactive Seed-Carried Biliary Stent of Rongsheng (Nanjing) Medical Technology Co., Ltd. is approved by NMPA. By far 200 innovative medical devices have been approved by NMPA.
-
Befotertinib Mesylate Capsules Approved for Marketing
2023-05-31
Recently, the Class I innovative product Befotertinib Mesylate Capsules (Chinese trade name: 赛美纳) of Betta Pharmaceuticals Co., Ltd. is approved by China NMPA.
-
Alfosbuvir Tablets Approved for Marketing
2023-05-17
Recently, the Class-1 innovative drug Alfosbuvir Tablets (Chinese trade name:圣诺迪) of Nanjing Sanhome Pharmaceutical Co., Ltd. is approved for marketing through the priority review and approval procedure by China NMPA.
-
Zuberitamab Injection Approved for Marketing
2023-05-17
Recently, the Zuberitamab injection (Chinese trade name: 安瑞昔) of Zhejiang BioRay Biopharmaceutical Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for the treatment of CD20 positive diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) for adult patients, and should be combined with standardized CHOP therapies (cyclophosphamide, doxorubicin, vincristine, prednisone).
-
COVID wave on decline, say experts
2023-06-16
The recent wave of COVID-19 is now trending downward, with experts saying China's medical system and the public have coped with the fresh outbreak in an orderly and calm manner.
